CSIMarket
 


Acura Pharmaceuticals inc  (ACUR)
Other Ticker:  
 

Acura Pharmaceuticals Inc's Working Capital Ratio

ACUR's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the forth quarter 2021, Working Capital Ratio deteriorated to 0.72 below Acura Pharmaceuticals Inc's average Working Capital Ratio.

Within Major Pharmaceutical Preparations industry 579 other companies have achieved higher Working Capital Ratio than Acura Pharmaceuticals Inc in forth quarter 2021. While Working Capital Ratio total ranking in the forth quarter 2021 has deteriorated compared to the prior quarter from 4350 to 5188.

Explain Working Capital Ratio
How much in Current Assets ACUR´s has?
What is the value of ACUR´s Current Liabilities?


ACUR Working Capital Ratio (Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
(Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
(Dec 31 2020)
IV. Quarter
Y / Y Current Liabilities Change -93.15 % -17.3 % -84.95 % 5.13 % 783.9 %
Y / Y Current Assets Change -68.45 % -47.94 % -32.53 % -0.65 % 0.08 %
Working Capital Ratio MRQ 0.72 0.86 1.18 0.18 0.16
ACUR's Total Ranking # 5188 # 4350 # 3916 # 4826 # 5799
Seq. Current Liabilities Change -47.45 % -11.71 % -85.55 % 2.15 % 534.77 %
Seq. Current Assets Change -55.98 % -35.45 % -5.08 % 16.96 % -27.36 %



Working Capital Ratio forth quarter 2021 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 580
Healthcare Sector # 1181
Overall Market # 5188


Working Capital Ratio Statistics
High Average Low
68.17 7.46 0.05
(Dec 31 2011)   (Mar 31 2019)




Financial Statements
Acura Pharmaceuticals Inc's Current Liabilities $ 1 Millions Visit ACUR's Balance sheet
Acura Pharmaceuticals Inc's Current Assets $ 0 Millions Visit ACUR's Balance sheet
Source of ACUR's Sales Visit ACUR's Sales by Geography


Cumulative Acura Pharmaceuticals Inc's Working Capital Ratio

ACUR's Working Capital Ratio for the trailling 12 Months

ACUR Working Capital Ratio

(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
(Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
(Dec 31 2020)
IV. Quarter
Y / Y Current Liabilities TTM Growth -93.15 % -17.3 % -84.95 % 5.13 % 783.9 %
Y / Y Current Assets TTM Growth -68.45 % -47.94 % -32.53 % -0.65 % 0.08 %
Working Capital Ratio TTM 0.38 0.27 0.31 0.26 0.26
Total Ranking TTM # 4918 # 4310 # 4311 # 4299 # 5884
Seq. Current Liabilities TTM Growth -47.45 % -11.71 % -85.55 % 2.15 % 534.77 %
Seq. Current Assets TTM Growth -55.98 % -35.45 % -5.08 % 16.96 % -27.36 %


On the trailing twelve months basis Current Liabilities decreased faster than Acura Pharmaceuticals Inc's average Current Assets, this led to increase in in Acura Pharmaceuticals Inc's Working Capital Ratio to 0.38, Working Capital Ratio remained below ACUR average.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 567 other companies have achieved higher Working Capital Ratio than Acura Pharmaceuticals Inc. While Working Capital Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2021 from 4310 to 4918.

Explain Working Capital Ratio
How much in Current Assets ACUR´s has?
What is the value of ACUR´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 568
Healthcare Sector # 1136
Within the Market # 4918


trailing twelve months Working Capital Ratio Statistics
High Average Low
3.89 1.13 0.14
(Sep. 30, 2015)   (Mar 31 2019)




Companies with similar Working Capital Ratio in the quarter ending Dec 31 2021, within Major Pharmaceutical Preparations Industry Working Capital RatioDec 31 2021 MRQ Current AssetsDec 31 2021 MRQ Current Liabilities
Scopus Biopharma Inc   1.96 $ 8.185  Millions$ 4.170  Millions
Spectrum Pharmaceuticals Inc   1.95 $ 103.952  Millions$ 53.229  Millions
Lifevantage Corp  1.93 $ 42.786  Millions$ 22.166  Millions
Kineta Inc   1.90 $ 43.074  Millions$ 22.663  Millions
Ptc Therapeutics inc   1.87 $ 954.368  Millions$ 509.348  Millions
Phasebio Pharmaceuticals Inc.  1.85 $ 48.784  Millions$ 26.336  Millions
Abbott Laboratories  1.85 $ 24,239.000  Millions$ 13,105.000  Millions
Johnson and Johnson  1.84 $ 60,979.000  Millions$ 33,131.000  Millions
Vtv Therapeutics Inc   1.84 $ 15.621  Millions$ 8.498  Millions
Jaguar Health inc   1.84 $ 28.434  Millions$ 15.471  Millions
Journey Medical Corporation  1.80 $ 84.493  Millions$ 46.946  Millions
Amryt Pharma Plc  1.80 $ 282.709  Millions$ 157.279  Millions
Dynavax Technologies Corporation  1.75 $ 972.520  Millions$ 556.402  Millions
Intercure Ltd   1.74 $ 336.160  Millions$ 193.585  Millions
Rockwell Medical inc   1.68 $ 35.288  Millions$ 20.966  Millions
Orgenesis Inc   1.68 $ 25.758  Millions$ 15.365  Millions
Endo International Plc  1.67 $ 2,714.586  Millions$ 1,629.962  Millions
Pacira Biosciences inc   1.66 $ 866.048  Millions$ 521.118  Millions
Biohaven Ltd   1.64 $ 876.254  Millions$ 534.202  Millions
Verrica Pharmaceuticals Inc   1.61 $ 74.328  Millions$ 46.055  Millions
Grifols Sa  1.59 $ 6,171.514  Millions$ 3,891.229  Millions
Clovis Oncology inc   1.58 $ 198.087  Millions$ 125.214  Millions
Athersys Inc  1.54 $ 46.027  Millions$ 29.861  Millions
Bristol myers Squibb Company  1.52 $ 33,262.000  Millions$ 21,868.000  Millions
Novartis Ag  1.51 $ 45,718.000  Millions$ 30,208.000  Millions
Aptevo Therapeutics Inc   1.51 $ 52.570  Millions$ 34.757  Millions
Baudax Bio Inc   1.50 $ 23.494  Millions$ 15.646  Millions
Medicure Inc   1.47 $ 9.616  Millions$ 6.520  Millions
Organon and Co   1.45 $ 3,760.000  Millions$ 2,597.000  Millions
Athenex Inc   1.43 $ 133.396  Millions$ 93.138  Millions

Date modified: 2023-07-01T11:47:39+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com